[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634352":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":63,"collaborators":32,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":32,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":32,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Suzetrigine (SUZ)","EXPERIMENTAL","Participants will receive SUZ for 14 days.",[13],"Drug: Suzetrigine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive placebo matched to SUZ for 14 days",[19],"Drug: Placebo",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Suzetrigine","Tablets for oral administration.",[9],[27,28],"VX-548","JOURNAVX",{"type":22,"name":15,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo matched to SUZ for oral administration",[15],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[40,54],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":32},"Legent Orthopedic and Spine Hospital","RECRUITING","Bellaire","Texas","77401","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-95.45883,29.70579,{"lat":52,"lon":51},{"facility":55,"status":42,"city":56,"state":44,"zip":57,"country":46,"countryCode":47,"cosmosGeoPoint":58,"geoPoint":62,"contacts":32},"Memorial Hermann Village Office","Houston","77043",{"type":49,"coordinates":59},[60,61],-95.36327,29.76328,{"lat":61,"lon":60},{"type":64,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100634352","phase-4-evaluation-of-pain-treatment-after-total-knee-arthroplasty-100634352",false,"NCT07538570","Evaluation of Pain Treatment After Total Knee Arthroplasty","A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty","Key Inclusion Criteria:\n\n* Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg\u002Fm\\^2)\n* Scheduled to undergo an elective primary unilateral TKA surgery\n\nKey Exclusion Criteria:\n\n\\- History of previous TKA surgery on incident side\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.","ALL","18 Years","80 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).",[83],"Pain","2026-05-08",{"date":86,"type":87},"2026-05-13","ACTUAL",{"date":89,"type":87},"2026-04-24",{"date":91,"type":77},"2027-01-30",{"name":5,"class":6},2]